# A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

> **NCT03873532** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hutchison Medipharma Limited** · enrollment: 298 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03873532
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-10
- **Primary completion:** 2021-06
- **Final completion:** 2022-03
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03873532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03873532, "A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03873532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*